Effective treatment of severe COVID-19 patients with tocilizumab

Abstract

Significance In patients with coronavirus disease 2019, a large number of T lymphocytes and mononuclear macrophages are activated, producing cytokines such as interleukin-6 (IL-6), which bind to the IL-6 receptor on the target cells, causing the cytokine storm and severe inflammatory responses in lungs and other tissues and organs. Tocilizumab, as a recombinant humanized anti-human IL-6 receptor monoclonal antibody, can bind to the IL-6 receptor with high affinity, thus preventing IL-6 itself from binding to its receptor, rendering it incapable of immune damage to target cells, and alleviating the inflammatory responses.

Keywords

TocilizumabMedicineCytokine stormCoronavirus disease 2019 (COVID-19)Internal medicineAdverse effectGastroenterologyInterleukin 6Oxygen therapyDiseaseCytokine

Affiliated Institutions

Related Publications

Lessons Learned to Date on COVID-19 Hyperinflammatory Syndrome: Considerations for Interventions to Mitigate SARS-CoV-2 Viral Infection and Detrimental Hyperinflammation

Marco Cardone , Masahide Yano , Amy S. Rosenberg +1 more

The first case of human transmission of SARS-CoV-2 was reported in China in December 2019. A few months later, this viral infection had spread worldwide and became a pandemic. T...

2020 Frontiers in Immunology 52 citations

Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome

Chun Kwok Wong , Charles Lam , Alan Wu +8 more

SUMMARY Severe acute respiratory syndrome (SARS) is a recently emerged infectious disease caused by a novel coronavirus, but its immunopathological mechanisms have not yet been ...

2004 Clinical & Experimental Immunology 1311 citations

Interleukin-6 Receptor Blockade Selectively Reduces IL-21 Production by CD4 T Cells and IgG4 Autoantibodies in Rheumatoid Arthritis

Gustavo Carbone , Augusta Wilson , Sean A. Diehl +3 more

Interleukin-6 (IL-6) levels are known to be increased in patients with rheumatoid arthritis (RA). Tocilizumab, a monoclonal antibody to the IL-6 receptor (IL-6R), reduces diseas...

2013 International Journal of Biological S... 66 citations

Clinical and immunological features of severe and moderate coronavirus disease 2019

Guang Chen , Di Wu , Wei Guo +17 more

BACKGROUNDSince December 2019, an outbreak of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in Wuhan, and is...

2020 Journal of Clinical Investigation 4983 citations

IL-6 in Inflammation, Immunity, and Disease

Toshio Tanaka , Masashi Narazaki , T Kishimoto

Interleukin 6 (IL-6), promptly and transiently produced in response to infections and tissue injuries, contributes to host defense through the stimulation of acute phase respons...

2014 Cold Spring Harbor Perspectives in Bi... 4591 citations

Publication Info

Year: 2020
Type: article
Volume: 117
Issue: 20
Pages: 10970-10975
Citations: 2754
Access: Closed

External Links

View on DOI.org

Social Impact

Altmetric

Effective treatment of severe COVID-19 patients with tocilizumab

PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

2754

OpenAlex

Cite This

APA Style

                            
                                
                                    Xiaoling Xu, 
                                
                                    Mingfeng Han, 
                                
                                    Tiantian Li
                                
                                et al.
                            
                            (2020). 
                            Effective treatment of severe COVID-19 patients with tocilizumab. 
                            Proceedings of the National Academy of Sciences
                            , 117
                            (20)
                            , 10970-10975.
                            https://doi.org/10.1073/pnas.2005615117
                        

Identifiers

DOI: 10.1073/pnas.2005615117